Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature.

World journal of surgical oncology - 18 Nov 2021

Xu Huanhuan, Liang Qi, Xu Xian, Tan Shanyue, Wang Sumeng, Liu Yiqian, Liu Lingxiang

Abstract excerpt

BACKGROUND: HER2 is a member of the ERBB family of receptor tyrosine kinases, and HER2 mutations occur in 1-4% of non-small cell lung cancer (NSCLC) as an oncogenic driver mutation. We found a rare mutation of HER2 p.Asp769Tyr in NSCLC. CASE PRESENTATION: We presented a case of a 68-year-old nonsmoking male patient with brain metastasis from lung adenocarcinoma harboring a rare mutation of HER2 p.Asp769Tyr. After...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Afatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Indoles

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Quinolines

Share to Receptor, ErbB-2

Source

Open in PubMed Open full text

Identifiers

PMID: 34794435
DOI: 10.1186/s12957-021-02444-7
PMCID: PMC8600784

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature.PMID 34794435Read ↗

Successful treatment of Afatinib plus Apatinib using for a lung adenocarcinoma patient with HER-2 V659D mutation: a rare case report.Semantic proximity Read ↗

Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report.Semantic proximity Read ↗

Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.Semantic proximity Read ↗

Efficacy generated by afatinib in a lung adenocarcinoma patient harboring HER2 S310Y mutation.Semantic proximity Read ↗

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review.Semantic proximity Read ↗

A case of multiple primary lung adenocarcinoma with a CD74-NRG1 fusion protein and HER2 mutation benefit from combined target therapy.Semantic proximity Read ↗

Response to furmonertinib in a patient with non-Small cell lung cancer harboring HER2 exon 21 insertion mutation : a case reportSemantic proximity Read ↗

Afatinib Plus Bevacizumab Treatment for a Patient With EGFR S645C-Mutant Non-Small Cell Lung Cancer: A Case Report.Semantic proximity Read ↗

Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.Semantic proximity Read ↗

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief ReportSemantic proximity Read ↗

Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review.Semantic proximity Read ↗

Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.